Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

(2012) Elena Cassinerio et al.   ANNALS OF HEMATOLOGY

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Efficacy of deferasirox in reducing and preventing cardiac iron overload in  -thalassemia

(2009) D. J. Pennell et al.   BLOOD

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

(2009) M. D. Cappellini et al.   HAEMATOLOGICA

High nontransferrin bound iron levels and heart disease in thalassemia major

(2008) Antonio Piga et al.   AMERICAN JOURNAL OF HEMATOLOGY

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

(2008) Shahina Daar et al.   EUROPEAN JOURNAL OF HAEMATOLOGY